SALT
LAKE CITY, Utah, March 18,
2024 /PRNewswire/ -- Co-Diagnostics,
Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular
diagnostics company with a unique, patented platform for the
development of molecular diagnostic tests, announced today that
Co-Dx CEO Dwight Egan will deliver
the keynote address at the 5th Annual Infectious Disease
Diagnostics and Molecular Diagnostics Conference, organized by
MarketsandMarkets and held March 21-22,
2024, in London,
England.
Mr. Egan will be delivering the keynote presentation at
9:00 am local time on March 21, and will be discussing impacts that the
Company's upcoming Co-Dx PCR platform* is anticipated to have on
the future of diagnostics accessibility.
The MarketsandMarkets Infectious Disease Diagnostics and
Molecular Diagnostics Conference is expected to gather influential
healthcare and industry leaders as they showcase the latest
insights in diagnostics, explore emerging technologies and their
applications, address challenges within the diagnostics domain and
the global need for improved healthcare. To learn more about the
event, including registration details, please visit here.
The following day on March 22 at
9:00 am local time, the Company's
Executive VP of Business Development Joseph Featherstone will also
be delivering a presentation titled "Accessible TB Diagnostics on
the Co-Dx PCR Pro in LMICs."
Attendees interested in learning more about the Company and its
products, including its upcoming Co-Dx PCR Pro™ instrument and
tests, are invited to visit the Company's booth.
*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™,
mobile app, and all associated tests) is subject to review by the
FDA and/or other regulatory bodies and is not yet available for
sale. The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are
currently under review by the FDA.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah
corporation, is a molecular diagnostics company that develops,
manufactures and markets state-of-the-art diagnostics technologies.
The Company's technologies are utilized for tests that are designed
using the detection and/or analysis of nucleic acid molecules (DNA
or RNA). The Company also uses its proprietary technology to design
specific tests for its Co-Dx PCR at-home and point-of-care platform
and to locate genetic markers for use in applications other than
infectious disease.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-ceo-to-deliver-keynote-address-at-marketsandmarkets-2024-in-london-england-302090883.html
SOURCE Co-Diagnostics